Jessica Marie Valdez, MD
Pediatric Medicine · Albuquerque
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Unm Medical Group Inc · 1,052 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Valdez’s office at (505) 272-2111 to ask if they take your plan before you enroll.
Medicaid work
$21,412 in 2024
Medicaid paid $21,412 for 154 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 100 | $14,562 |
| Long return visit (40+ min) | 54 | $6,850 |
| 2024 | 154 | 2 | 15 | $21,412 |
| 2023 | 88 | 1 | 20 | $8,806 |
| 2022 | 61 | 2 | 13 | $4,977 |
| 2021 | 31 | 1 | 12 | $2,965 |
| 2020 | 39 | 2 | 14 | $3,587 |
| 2019 | 26 | 1 | 13 | $2,009 |
| 2018 | 14 | 1 | 12 | $1,127 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 88 | $8,806 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $2,772 |
| Long return visit (40+ min) | 26 | $2,205 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $2,965 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $2,467 |
| Long return visit (40+ min) | 14 | $1,120 |
2019
| Long return visit (40+ min) | 26 | $2,009 |
2018
| Long return visit (40+ min) | 14 | $1,127 |
Money from drug and device companies
$1,910 in 2025
| 2025 | 3 | 8 | $1,590 | $1,910 |
| 2024 | 3 | 4 | None | $378 |
| 2023 | 2 | 2 | None | $88 |
| 2022 | 2 | 2 | None | $265 |
| 2019 | 1 | 1 | None | $124 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Day One Biopharmaceuticals | Ojemda | $1,678 | 3 payments
|
| Jazz Pharmaceuticals | Rylaze | $198 | 4 payments
|
| Abbvie | Imbruvica | $34 | 1 payment
|
See all 8 published payments
| Day One Biopharmaceuticals | Consulting · 2025-12-18 | Ojemda | $1,590 |
| Abbvie | Meals · 2025-12-02 | Imbruvica | $34 |
| Day One Biopharmaceuticals | Meals · 2025-11-13 | Ojemda | $19 |
| Jazz Pharmaceuticals | Meals · 2025-10-01 | Rylaze | $31 |
| Jazz Pharmaceuticals | Meals · 2025-08-02 | Rylaze | $124 |
| Day One Biopharmaceuticals | Meals · 2025-07-29 | Ojemda | $70 |
| Jazz Pharmaceuticals | Meals · 2025-03-25 | Rylaze | $36 |
| Jazz Pharmaceuticals | Meals · 2025-03-11 | Rylaze | $7 |
See earlier years (2024, 2023, 2022, 2019)
2024: $378
| Day One Biopharmaceuticals | Ojemda | $141 | 2 payments
|
| Uswm | Iwilfin | $119 | 1 payment
|
| BTG International | Voraxaze | $118 | 1 payment
|
2023: $88
| Adaptive Biotechnologies | Clonoseq | $72 | 1 payment
|
| Servier Pharmaceuticals | None | $16 | 1 payment
|
2022: $265
| Jazz Pharmaceuticals | Rylaze | $147 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $118 | 1 payment
|
2019: $124
| Genentech USA | Hemlibra | $124 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2022 | Their institution | $273,950 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2021 | Their institution | $66,610 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pediatric Ph+ All - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added To Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 2023 | Their institution | $3,000 |
| Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2023 | Their institution | $1,000 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750673661
- Licence
- NM MD2018-0137
- Trained
- University of New Mexico School of Medicine, 2011
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 800 Bradbury Dr Se Ste 116, Albuquerque, NM, 87106
- NPI first listed
- 2011-05-11
- NPI last updated
- 2024-10-29
- NPI record certified
- 2024-10-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 262 Danny Thomas Pl, Memphis, TN, 38105 · 725 Welch Rd, Palo Alto, CA, 94304
This office lists an electronic records connection.